Quantix Italia: technology hand in hand with regenerative medicine
An expanding reality whose aim is the stimulation of the regeneration and repair capacities of the human organism
A startup that wants to improve patients’ quality of life, but how? We are talking about Quantix Italia, a reality founded in 2018 in Milan from the idea of a group of entrepreneurs and managers who are experts in the field of regenerative medicine, a branch of medicine that aims to cure chronic diseases to solve problems for patients with degenerative diseases. Telling us about it was Federico Costa, owner.
‘ Quantix Italia will continue to carry out research and development activities in the future in order to create new product lines in both medical devices and cosmetics. ’
In its first three years of existence, Quantix Italia awarded contracts for research and development activities with a number of universities, in particular the University of Insubria in Varese, and also with companies through which they now carry out a number of projects. With one of these they have entered into a collaboration related to the development of a class 3 medical device in the orthopaedic and aesthetic fields. In 2021, the company obtained a licence for the first patent corresponding to the product of one of their medical devices called Idria of which they are very proud and of which they marketed the first sales in 2023. This year was the startup’s breakthrough year because three medical devices were launched on the market, thanks to which they were able, at first, to consolidate domestic trade and, now, also the market on an international level, which will boost sales. At the end of 2023, the international market accounted for about 15 per cent, now they aim to double this percentage to become an international start-up.
The company has a pipeline of three products with different models inside: all of them deal with the processing of peripheral blood to obtain a platelet-rich plasma from which there are biological components that are concentrated and reintroduced into the patient’s tissue to treat a chronic disease in the orthopaedic and vascular fields. Their work is to help patients through the grafting of appropriately engineered human tissues by healing those tissues that were previously damaged. At present, their customers are distributors operating nationally and internationally, who later retail the products to hospitals and private medical practices that are licensed to treat human tissue.
